SCHEMBL10198005

SCHEMBL10198005

CC(=O)C(C)(C)[C@](C)(N)c1cc(Br)ccc1F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 1/20 0.40
PTGDR2 Q9Y5Y4 1/20 0.36
LMNA P02545 5/20 0.33
NPC1 O15118 3/20 0.33
ALDH1A1 P00352 3/20 0.33
RAB9A P51151 3/20 0.33
SMN1; SMN2 Q16637 3/20 0.33
KMT2A Q03164 2/20 0.33
GAA P10253 2/20 0.33
AAK1 Q2M2I8 2/20 0.32
TSHR P16473 1/20 0.31
KDM4E B2RXH2 1/20 0.31
GLA P06280 1/20 0.31
RBP4 P02753 1/20 0.31
MEN1 O00255 1/20 0.31
MAPT P10636 1/20 0.31
HPGD P15428 1/20 0.31
ALOX12 P18054 1/20 0.31
CASP3 P42574 1/20 0.31
SENP7 Q9BQF6 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL569110 0.84 SMN1; SMN2 (0.39) DGAT1PTGDR2LMNANPC1ALDH1A1
SCHEMBL569109 0.84 SMN1; SMN2 (0.39) DGAT1PTGDR2LMNANPC1ALDH1A1
SCHEMBL1173705 0.80 DGAT1 (0.41) DGAT1PTGDR2LMNANPC1ALDH1A1
SCHEMBL1173702 0.80 DGAT1 (0.41) DGAT1PTGDR2LMNANPC1ALDH1A1
SCHEMBL246150 0.78 DGAT1 (0.42) DGAT1PTGDR2LMNANPC1ALDH1A1
SCHEMBL1173288 0.78 DGAT1 (0.42) DGAT1PTGDR2LMNANPC1ALDH1A1
SCHEMBL14889830 0.78 DGAT1 (0.42) DGAT1PTGDR2LMNANPC1ALDH1A1
SCHEMBL10197999 0.77 KCNN4 (0.45) ALDH1A1RAB9AGAAKDM4EALOX12
SCHEMBL10197985 0.77 ALDH1A1 (0.45) LMNAALDH1A1SMN1; SMN2KMT2AGAA
SCHEMBL1973906 0.76 DGAT1 (0.38) DGAT1PTGDR2LMNANPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140336208-A1 1,4,5,6-TETRAHYDRO-PYRIMIDIN-2-YLAMINE COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2014-11-13 US disclosed
US-8815881-B2 1,4,5,6-tetrahydro-pyrimidin-2-ylamine compounds HOFFMANN-LA ROCHE INC. (US) 2014-08-26 US disclosed
US-20120035195-A1 1,4,5,6-TETRAHYDRO-PYRIMIDIN-2-YLAMINE COMPOUNDS SIENA BIOTECH S.P.A., AN ITALIAN COMPANY (IT) 2012-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140336208-A1 1,4,5,6-TETRAHYDRO-PYRIMIDIN-2-YLAMINE COMPOUNDS BACE2, BACE1, PSEN2 DGAT1 3613/4885PTGDR2 1261/4885LMNA 3282/4885
US-20120035195-A1 1,4,5,6-TETRAHYDRO-PYRIMIDIN-2-YLAMINE COMPOUNDS BACE2, BACE1, PSEN2 DGAT1 3613/4885PTGDR2 1261/4885LMNA 3282/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.